Interim Results From Gentium S.p.A.'s Treatment IND For Defibrotide And Additional Data On Defibrotide In The Prevention Of Acute Graft Versus Host Disease (Agvhd) Presented At The American Society of Hematology Annual Meeting
Published: Dec 11, 2013
VILLA GUARDIA (COMO), Italy, Dec. 11, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that additional data on Defibrotide were presented this week at the 55th Annual Meeting and Exposition of the American Society of Hematology at the Ernst N. Morial Convention Center in New Orleans, LA, December 7-10, 2013.
Help employers find you! Check out all the jobs and post your resume.